RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Preclinical highlights： EVM14 induced a dose-dependent, antigen-specific immune response in mice and significantly inhibited tumor growth in multiple syngeneic tumor models. As a therapeutic ...